Compare Ascendis Pharma A/S (ASND) vs Beyond Meat Inc (BYND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Beyond Meat Inc — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Beyond Meat Inc trades at $0.66 (market cap $338.06M). The key difference: Ascendis Pharma A/S is far larger — about 52.5× Beyond Meat Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| ASND | BYND | |
|---|---|---|
Market Cap | $17.74B | $338.06M |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $4.28 |
52-Week Low | $163.32 | $0.52 |
Enterprise Value | $18.11B | $648.06M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BYND trades at $0.656, down 2.77% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with a net income margin of 79.49% but negative operating cash flow of -$144.93M in 2025. Recent product expansions include Beyond Steak Filet at Meijer and Wegmans, while earnings have been volatile with two misses and one beat in the last four quarters.
The outlook remains challenging with 57% analyst sell ratings and declining revenue trends. Key risks include persistent cash burn and competitive pressures. Upside potential hinges on successful turnaround efforts through new product launches and cost management, but the stock faces significant headwinds near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
